Home » Business, Health & Medicine, Hospitality » Abicipar Pegol (Macular Edema and Macular Degeneration) Market Share And Forecasts To 2023
“http://origin.grandviewresearc.netdna-cdn.com/img/logo.png”
Radiant Insights, Inc The Title “Abicipar Pegol (Macular Edema and Macular Degeneration) Market Size ,Shares, Trends, Analysis And Forecasts To 2023” Has Been Added To New Report Database

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world.

Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector.

Access Full Report:
http://www.radiantinsights.com/research/abicipar-pegol-macular-edema-and-macular-degeneration-forecast-and-market-analysis-to-2023

The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

Read This Report On the linkedIn:
https://www.linkedin.com/pulse/abicipar-pegol-market-growth-report-2023-dev-maskare 

Allergan’s abicipar pegol is a novel, long-acting anti-VEGF drug that is based on the DARPin technology. It is undergoing clinical development as a potential treatment for patients with wAMD, and a Phase III clinical trial is expected to begin in Q2 2015.

Scope

• Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Abicipar Pegol including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Abicipar Pegol for the top country from 2013 to 2023.
• Sales information covered for the US, France, Germany, Italy, Spain, UK and Japan


About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For More Information, Visit: Radiant Insights


Read Other Reports

Liquid Paraffin Market:
http://www.radiantinsights.com/research/global-and-chinese-liquid-paraffin-industry-2009-2019-market-research-report

Acrylic Tow Market:
http://www.radiantinsights.com/research/global-and-chinese-acrylic-tow-industry-2009-2019-market-research-report

Media Contact
Company Name: Radiant Insights, Inc.
Contact Person: Michelle Thoras, Corporate Sales Specialist – USA
Email: sales@radiantinsights.com
Phone: (415) 349-0054, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
State: Califonia
Country: United States
Website: http://www.radiantinsights.com/research/abicipar-pegol-macular-edema-and-macular-degeneration-forecast-and-market-analysis-to-2023

Comments are closed.